ClarVista is a privately held, clinical- and commercial-stage ophthalmology device company concentrating solely on the development of the Harmoni modular intraocular lens (IOL) system. While surgical instrumentation and biometry devices have rapidly progressed and improved in the past decade, the fundamental design of the IOL has not. Surgeons (and patients) have, therefore, come to tolerate unpredictable outcomes and potential complications (such as posterior capsule opacification). ClarVista attributes the challenge of ensuring a predictable lens position to the movement encountered during phacoemulsification procedures with traditional IOLs. Couple unpredictable lens positions with the added difficulty of IOL calculations in the almost 20 million people in the US who have undergone refractive surgery and “refractive outcomes will continue to be a challenge,” President and CEO Paul McLean said.
For more in Ophthalmology innovation visit:
[ Ссылка ]
